(FM) Inmunología
Departamento académico
Gustave Roussy Cancer Campus
Villejuif, FranciaPublicaciones en colaboración con investigadores/as de Gustave Roussy Cancer Campus (11)
2024
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641
-
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
2023
-
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022
Annals of Oncology, Vol. 34, Núm. 1, pp. 48-60
2022
-
Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers
ESMO Open, Vol. 7, Núm. 2
2021
-
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Nature Reviews Clinical Oncology, Vol. 18, Núm. 9, pp. 558-576
2018
-
Starting the fight in the tumor: Expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)
Annals of Oncology, Vol. 29, Núm. 11, pp. 2163-2174
2017
-
Predictors of responses to immune checkpoint blockade in advanced melanoma
Nature Communications, Vol. 8, Núm. 1
2014
-
Classification of current anticancer immunotherapies
Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508
-
Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013
Journal of Translational Medicine, Vol. 12, Núm. 1
2011
-
Defining the critical hurdles in cancer immunotherapy
Journal of Translational Medicine